GLP-1 Medications and Addiction: What the Research Shows
Emerging research reveals GLP-1 medications like semaglutide may reduce cravings for alcohol, opioids, and nicotine by targeting the brain's reward system. Here's what the science shows.
Medically Reviewed
Reviewed by Dr. James Chen, MD, PhD, FACE on April 20, 2026
Our medical review process ensures clinical accuracy and patient safety.
When patients on semaglutide or tirzepatide for weight loss began reporting something unexpected — they were drinking less alcohol, finding cigarettes less appealing, even losing interest in opioids — researchers took notice. What started as anecdotal reports has rapidly evolved into one of the most exciting frontiers in addiction medicine.
A 2024 analysis of over 682,000 individuals found that those taking semaglutide had approximately 50% lower risk of developing alcohol use disorder compared to patients on other anti-obesity medications.
Evidence: "GLP-1 receptor agonist use was associated with a 50% lower risk of new AUD diagnosis and, among individuals with prior AUD, a 50% lower recurrence rate" — Volkow ND, et al. Addiction. 2025. DOI: 10.1111/add.16626
This isn't a coincidence. GLP-1 receptors are expressed throughout the brain's reward circuitry — the same system hijacked by addictive substances. Understanding why these medications dampen addictive behaviors may redefine how medicine approaches substance use disorders.
How GLP-1 Affects the Brain's Reward System
Most people know GLP-1 (glucagon-like peptide-1) as a gut hormone that regulates blood sugar and appetite. But GLP-1 receptors are also densely distributed in the mesolimbic dopamine system — the brain's primary reward and motivation network.
This system includes the nucleus accumbens, ventral tegmental area (VTA), and prefrontal cortex. When you consume alcohol, use opioids, or smoke a cigarette, these structures flood with dopamine, producing the reinforcing "high" that drives repeated use.
GLP-1 receptor agonists appear to blunt this response in two ways:
- Direct dopamine modulation: GLP-1 receptors in the VTA suppress dopamine neuron firing, reducing the intensity of reward signals triggered by addictive substances
- Reduced craving signals: By activating hypothalamic and prefrontal circuits, GLP-1 drugs appear to dampen anticipatory craving — the urge to seek out a substance before use
Evidence: "GLP-1 receptor agonists modulate dopamine transmission in the nucleus accumbens and reduce the rewarding properties of addictive substances across multiple preclinical models" — Mechanisms of GLP-1 in Modulating Craving and Addiction: Neurobiological and Translational Insights. PMC. 2025. PMC12372146
This mechanism is fundamentally different from existing addiction treatments, most of which target specific opioid receptors (naltrexone, buprenorphine) or stress pathways (acamprosate). GLP-1 drugs act upstream, at the level of dopamine itself, which may explain their broad-spectrum effect across multiple substance categories.
Alcohol Use Disorder: The Strongest Evidence
The most rigorous clinical data comes from a 2025 randomized controlled trial published in JAMA Psychiatry. Researchers enrolled 48 adults with alcohol use disorder and randomized them to weekly semaglutide injections (escalating from 0.25 mg to 1.0 mg) or placebo over 9 weeks.
What the trial found:
| Outcome | Semaglutide | Placebo | P-value |
|---|---|---|---|
| Grams of alcohol consumed (lab task) | Significantly reduced | Baseline | P = .01 |
| Peak breath alcohol concentration | Significantly reduced | Baseline | P = .03 |
| Drinks per drinking day | Reduced | No change | Significant |
| Weekly alcohol craving | Reduced | No change | Significant |
| Heavy drinking days | Greater reduction over time | Less reduction | Significant |
Evidence: "Semaglutide reduced alcohol consumed during a laboratory self-administration task with medium-to-large effect sizes (β = −0.48; 95% CI, −0.85 to −0.11; P = .01)" — Hendershot CS, et al. JAMA Psychiatry. 2025;82(4):395–405. DOI: 10.1001/jamapsychiatry.2024.4789
Notably, the trial used low doses of semaglutide — lower than the standard weight-loss doses — and still achieved significant reductions. This suggests the anti-addiction effect may operate through mechanisms partially distinct from appetite suppression.
A 2024 systematic review in The Lancet eClinicalMedicine analyzed 6 studies including 2 RCTs with over 88,000 combined participants. While the authors noted the evidence base is still developing, subgroup analyses and observational data consistently pointed in the same direction: GLP-1 receptor agonists reduce alcohol consumption and improve AUD-related outcomes.
Evidence: "Subgroup analysis from two RCTs and four observational studies suggest that GLP-1 RAs may reduce alcohol consumption and improve outcomes in some individuals" — eClinicalMedicine (The Lancet). 2024. DOI: 10.1016/j.eclinm.2024.102920
Opioid Use Disorder: Promising Real-World Data
Real-world evidence from over half a million patients with opioid use disorder (OUD) has begun to emerge. A landmark real-world analysis examined electronic health records from 136 U.S. health systems and found that patients prescribed GLP-1 receptor agonists had a 40% lower rate of opioid overdose during a 2-year follow-up compared to matched controls not on GLP-1 therapy.
Evidence: "Among patients with prior opioid use disorder, those prescribed GLP-1/GIP receptor agonists had approximately 40% lower rates of opioid overdose events during the 2-year follow-up period" — Qeadan F, et al. Addiction. 2025;120(2):236–250. DOI: 10.1111/add.16679
This is a striking finding, because reducing opioid overdose is one of the hardest problems in addiction medicine. Existing medications like naltrexone and buprenorphine require daily adherence; GLP-1 receptor agonists are already being used weekly or monthly for obesity and diabetes, meaning patients may receive addiction-related benefits passively.
Preclinical studies provide a mechanistic basis for this effect: in rodent models, GLP-1 receptor agonists reduced self-administration of heroin, fentanyl, and oxycodone. The effect appears driven by blunted dopaminergic reward signaling rather than direct opioid receptor antagonism — meaning GLP-1 drugs don't block the opioid receptor the way naltrexone does, but rather reduce the brain's motivation to seek the drug in the first place.
It is important to note that at least one earlier preclinical study found GLP-1 receptor agonist treatment did not reduce abuse-related effects of opioids in certain paradigms. The picture is still being clarified, and clinical trials specifically for OUD are underway.
Nicotine and Smoking Cessation
For nicotine, most of the current evidence comes from animal models and observational data. GLP-1 receptor agonists have been shown to reduce:
- Nicotine self-administration in rodents
- Reinstatement of nicotine seeking after withdrawal
- Locomotor stimulation in response to nicotine
From a clinical standpoint, observational data have found GLP-1 use associated with significantly lower rates of new nicotine use disorder diagnoses. A broad-spectrum population study found a 20% reduction in the risk of developing nicotine dependence among GLP-1 users.
An additional benefit: one of the primary barriers to smoking cessation is weight gain. GLP-1 medications, which cause significant weight loss independently, could remove this barrier — offering a dual advantage for smokers trying to quit.
Clinical trials specifically examining GLP-1 drugs as smoking cessation aids are underway, including at least two trials in the U.S. and Europe. Results are expected in 2025–2026.
Broader Addiction Effects: Cocaine, Cannabis, and Beyond
The broad-spectrum nature of GLP-1's effect on addiction risk is perhaps its most surprising feature. A population-level analysis found that GLP-1 use was associated with:
- 18% lower risk of developing alcohol use disorder
- 20% lower risk of cocaine use disorder
- 20% lower risk of nicotine dependence
- 25% lower risk of opioid use disorder
- 14% lower risk of cannabis use disorder
- 14% lower overall risk of any substance use disorder
These numbers suggest that GLP-1 receptor agonists are not acting through a substance-specific mechanism but rather through a shared upstream pathway — dopamine reward circuitry — that underlies the reinforcing properties of virtually all addictive substances.
This does not mean these drugs should be viewed as a universal cure. Population-level risk reductions reflect averages across diverse individuals, and the effect size varies considerably based on the substance, dose, duration of treatment, and individual neurobiology.
Limitations and Open Questions
Despite the excitement, significant questions remain:
What is the optimal dose? The JAMA Psychiatry RCT used lower-than-standard doses. It is unclear whether higher doses provide greater anti-addiction effects or whether the relationship is non-linear.
How long must treatment continue? Most of GLP-1's addiction-related benefits appear tied to active use. Whether short treatment courses induce lasting neurobiological changes — or whether benefits reverse upon discontinuation — is not yet established.
Who benefits most? Early data suggest individuals with higher baseline craving or reward sensitivity may derive the greatest benefit. Pharmacogenomic research into GLP-1 receptor variants could help identify responders.
Are there addiction-specific safety concerns? Standard GLP-1 side effects (nausea, vomiting, gastrointestinal distress) are well characterized. However, the psychiatric safety profile in individuals with active substance use disorders — who often have elevated rates of depression and anxiety — requires careful prospective study.
FDA approval is not yet here. As of April 2026, no GLP-1 receptor agonist is FDA-approved for the treatment of any substance use disorder. Clinicians may prescribe them off-label in patients who also qualify for approved indications (obesity, type 2 diabetes), but coverage for addiction-specific use is not established.
Key Takeaways
The evidence that GLP-1 receptor agonists reduce addictive behaviors is accumulating rapidly — from mechanistic preclinical studies to randomized controlled trials and large real-world datasets. The data are most robust for alcohol use disorder, where a phase 2 RCT and multiple observational studies converge on a consistent effect.
The proposed mechanism — dampening of mesolimbic dopamine signaling — provides a plausible and drug-class-consistent explanation for why these benefits extend across alcohol, opioids, nicotine, and other substances.
For patients already prescribed GLP-1 medications for obesity or diabetes who also struggle with substance use, these findings offer a meaningful secondary benefit worth discussing with a physician. For the field of addiction medicine, GLP-1 receptor agonists represent one of the most promising new pharmacological approaches in decades.
More than 15 clinical trials are currently active globally. The next two years will be pivotal in determining whether these medications earn a formal role in the treatment of substance use disorders.
If you are currently taking a GLP-1 medication and struggling with alcohol or other substances, speak with your prescribing physician. For patients not already on these medications, evidence is not yet sufficient to start them solely for addiction treatment — but clinical trial participation may be an option. You can also explore our guide to GLP-1 medications and mental health for additional context on how these drugs affect the brain.
References
Volkow ND, et al. GLP-1R agonist medications for addiction treatment. Addiction. 2025. DOI: 10.1111/add.16626 | PubMed
Hendershot CS, et al. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2025;82(4):395–405. DOI: 10.1001/jamapsychiatry.2024.4789 | PubMed
Association between glucagon-like peptide-1 receptor agonists use and change in alcohol consumption: a systematic review. eClinicalMedicine (The Lancet). 2024. DOI: 10.1016/j.eclinm.2024.102920 | PubMed
Qeadan F, et al. The association between GIP and/or GLP-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders: A real-world data analysis. Addiction. 2025;120(2):236–250. DOI: 10.1111/add.16679 | PubMed
Mechanisms of GLP-1 in Modulating Craving and Addiction: Neurobiological and Translational Insights. PMC. 2025. PMC12372146
GLP-1 Therapeutics and Their Emerging Role in Alcohol and Substance Use Disorders: An Endocrinology Primer. PMC. 2025. PMC12509273
Last updated: 2026-04-20 Medical review: Dr. James Chen, MD, PhD, FACE
Tags
Written By
Dr. Sarah Mitchell
Medical Director, MD, FACP
Dr. Sarah Mitchell is a board-certified internist specializing in metabolic medicine and weight management. With over 15 years of clinical experience, she has helped thousands of patients achieve sustainable weight loss through evidence-based approaches.
Medical Reviewer
Dr. James Chen
Endocrinologist, MD, PhD, FACE
Dr. James Chen is a fellowship-trained endocrinologist with expertise in diabetes, metabolism, and hormone-related weight disorders. His research on GLP-1 receptor agonists has been published in leading medical journals.
Editorial Standards
This article follows our strict editorial guidelines. All content is based on peer-reviewed research and reviewed by medical professionals. This information is for educational purposes only — always consult your healthcare provider before making medical decisions.